1. Global Initiative for Asthma. Workshop Report, 2011. http://www.ginasthma.com/download.asp?intId=217
2. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94 (2): 187–226.
3. Holgate S, Dahlen S-E. SRS-A to Leukotrienes, 1997.
4. O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111: 27S–34S.
5. Shore S. Obesity and asthma: lessons from animal models. J Appl Physiol 2007; 102: 516–28.
6. Hernandez-Alvidrez E, Alba-Reyes G, Munoz-Cedillo BC et al. Passive smoking induces leukotriene production in children: influence of asthma. J Asthma [Epub ahead of print], Feb. 12, 2013.
7. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis and management. J Clin Immunol 1999; 104: 5–13.
8. Hedman J, Kaprio J, Poussa T et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int J Epidemiol 1999; 717–22.
9. McMains, Christopher K, Kountakis, Stilianos E. Medical and surgical considerations in patients with Samter's triad. OceanSide Publications, Inc. American J Rhinology 2006; 20 (6): 573–6.
10. Княжеская Н.П. Аспириновая бронхиальная астма и антагонисты лейкотриенов. РМЖ. 2000; 8 (12): 505–9.
11. Anderson SD, Kippelen P. Exercise-induced bronchoconstriction: pathogenesis. Curr Allergy Asthma Rep 2005; 5: 116–22. 
12. Carlsen K-H. Paediatric exercise testing in respiratory illness. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy. March 2–4, 2006; ERS School Courses 2006.
13. McFadden ER, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330: 1362.
14. Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy. March 2–4, 2006; ERS School Courses 2006.
15. Teal S. Hallstrand. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr 2002; 141: 343–9.
16. Чучалин А.Г. Спорт и бронхиальная астма. Пульмонол. и аллергол. 2005; 2: 3–5. 
17. Chalmers GW, Macleod KJ, Little SA et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–30.
18. Chaudhuri R, Livingston E, McMahon AD et al. Cigarette smoking impairs the therapeutic response to oralcorticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168 (11): 1308–11.
19. Tomlinson JEM, McMahon AD, Chaudhuri R et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60 (4): 282–7.
20. Livingston E, Chaudhuri R, McMahon AD et al. Systemic sensitivity to corticosteroids in smokers withasthma. Eur Respir J 2007; 29 (1): 64–71.
21. Beuther DA, Sutherland ER. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175: 661–6.
22. Schachter LM, Peat JK, Salome CM. Asthma and atopy in overweight children. Thorax 2003; 58: 1031–5.
23. Лопатин А.С., Гущин И.С., Емельянов А.В. и др. Клинические рекомендации по диагностике и лечению аллергического ринита. Cons. Med. 2001; Прил.: 33–44.
24. Вылегжанина Т.Г. Взаимосвязь аллергического ринита и бронхиальной астмы. Cons. Med. 2001; 3 (12): 579–81.
25. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154: S21–7.2.
26. Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax 2003; 58: 3 204–210 doi:10.1136/thorax.58.3.204.
27. Joos S, Miksch A, Szecsenyi J et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63 (5): 453–62. 
28. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009; 16 (Suppl. A): 17A–31A.
29. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med 2010; 104 (5): 644–51.
30. Price DB, Swern A, Tozzi CA et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–2.
31. Murai A, Abe M, Hayashi Y et al. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist, montelukast, and methylprednisolone. J Pharmacol Exp Ther Online Oct. 6, 2004.
32. Braunstahl G-J, Kleinjan A, Overbeek SE et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161: 2051–7.
33. Stirling RG, Chung KF. Leukotriene antagonists and Churg–Strauss syndrome: the smoking gun. Thorax 1999; 54: 865–6.

Н.П.Княжеская 

Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва